Rilpivirine

CHEMBL175691 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
366.4 g/mol
LogP
4.5
Phase
4

A non-nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy for HIV-1 infection in treatment-naive patients with low viral loads. It is taken once daily and is available in combination pills that simplify HIV treatment regimens.

Peso molecular

366,4000 g/mol

LogP

4,50

TPSA

97,40 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Mecanismo de acción

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1

InChI

InChI=1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)/b4-3+

Molecular Formula

C22H18N6

HBD / HBA

2 / 6

Enlaces Rotables

5

Átomos Pesados

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A non-nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy for HIV-1 infection in treatment-naive patients with low viral loads. It is taken once daily and is available in combination pills that simplify HIV treatment regimens.

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Yes, Rilpivirine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL175691. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6451164. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.